<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03687541</url>
  </required_header>
  <id_info>
    <org_study_id>35RC18_3089_HEMO-CIH</org_study_id>
    <nct_id>NCT03687541</nct_id>
  </id_info>
  <brief_title>In-hospital Falls and Hemorrhagic Complications : a Descriptive Analysis in Rennes University Hospital</brief_title>
  <acronym>HEMO-CIH</acronym>
  <official_title>In-hospital Falls and Hemorrhagic Complications : a Descriptive Analysis in Rennes University Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anticoagulant and antiplatelet treatments have well defined indactions, with a clearly proved&#xD;
      benefit, respectivly for prevention of arterial and venous emblism and for prevention of&#xD;
      athermo-related arterial thrombosis.&#xD;
&#xD;
      Bleeding risk represents the main adverse effect of these antithrombotic medications. Then&#xD;
      benefit-risk ratio is sometimes difficult to evaluate, especially for elderly patients prone&#xD;
      to fall (incidence of falls estimated to 30% per year for patients over 65), exposed on the&#xD;
      one hand to thromboembolic risk and on the other hand to bleeding risk.&#xD;
&#xD;
      Associations between falls and antithrombotic-related bleeding risk had already been&#xD;
      evaluated in several studies :&#xD;
&#xD;
        -  Concerning anticoagulant treatments in patients at high risk of falls, retrospective&#xD;
           studies shown a overrated risk of intracranial hemorrhage and mortality, but those&#xD;
           results remain discordant wtih 3 major prospective studies on larger populations.&#xD;
&#xD;
        -  Concerning antiplatelet treatments in patients at high risk of falls, majority of&#xD;
           retrospective studies reported an overrated risk of major bleeding, intracranial&#xD;
           bleeding and mortality, but datas remain fewer than for anticoagulant and results are as&#xD;
           well discordant with prospective studies.&#xD;
&#xD;
        -  No difference of morbi-mortality is clearly estalblished depending of antithrombotic&#xD;
           treatment class (anticoagulant versus antiplatelet), however there is a cumulative risk&#xD;
           in case of association of both anticoagulant and antiplatelet.&#xD;
&#xD;
        -  Main factors associated with fall-related bleeding for patients on anticoagulant include&#xD;
           age, female sex, anemia, chronic kidney disease, dementia and polymedication.&#xD;
&#xD;
      Thus, the purpose of this study is to specify whether occurrence of falls justify to&#xD;
      reconsider prescription of antithrombotic treatments in patients having an indication of&#xD;
      antiplatelet or anticoagulant therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retrospective, descriptive and non-interventional study over a period of 12 months (from&#xD;
      01/01/2017 to 31/12/2017), from unwanted events database of Rennes University Hospital.&#xD;
&#xD;
      Patients meeting criterias receive an information mail. Without opposition over a period of 3&#xD;
      weeks, datas will be treated, focusing on the event and its consequencies until hospital&#xD;
      outing.&#xD;
&#xD;
      Baseline characteristics :&#xD;
&#xD;
        -  Demographic datas : age, sex&#xD;
&#xD;
        -  Antithrombotic treatement, treatment class and molecule&#xD;
&#xD;
        -  Last INR dosage before the fall for patients of vitamin K antagonists&#xD;
&#xD;
        -  Antithrombotic treatment indication : supra-ventricular arythmia, heart valve mecanical&#xD;
           prothesis, severe left ventricle hypokinesia, venous thromboembolism, anti-phospholipid&#xD;
           syndrome, myeloproliferative disorder, atheroma (in primary or secondary prevention)&#xD;
&#xD;
        -  Comorbidities : history of bleeding (including hemorrhagic stroke), haemostasis&#xD;
           disorder, thrombocytopenia, anemia, chronic kidney disease, chronic liver disease,&#xD;
           alcohol abuse, ischemic stroke or transient ischemic stroke, cognitive disoreder, active&#xD;
           neoplasm, HAS-BLED score, HEMORRHAGE score&#xD;
&#xD;
        -  Other undergoing treatments : total number of medications, antihypertensive treatment,&#xD;
           psychotropic treatment, non-steroid anti-inflamatory treatment&#xD;
&#xD;
      Description of fall-related bleeding events rate (until hospital outing) according to the&#xD;
      severity :&#xD;
&#xD;
        -  Any severity bleedings&#xD;
&#xD;
        -  Major bleedings (hemorrhagic shock, deglobulisation, red blood cells transfusion&#xD;
           required, vital or functional-threatening bleeding spot, uncontrolled hemorrhage&#xD;
           requiring specialized haemostatic intervention)&#xD;
&#xD;
        -  Intracranial bleeding&#xD;
&#xD;
        -  Fatal bleeding&#xD;
&#xD;
      Modification of the antithrombotic prescription in the aftermath of the fall :&#xD;
&#xD;
      - Discontinuation or suspension of antithrombotic treatment&#xD;
&#xD;
      Sub-group analysis for each previous item, according to undergoing antithrombotic treatment&#xD;
      at the moment of the fall :&#xD;
&#xD;
        -  Curative-dose anticoagulant in monotherapy&#xD;
&#xD;
        -  Preventive-dose anticoagulant in monotherapy&#xD;
&#xD;
        -  Antiplatelet in monotherapy&#xD;
&#xD;
        -  Curative-dose anticoagulant and antiplatelet in association&#xD;
&#xD;
        -  Preventive-dose anticoagulant and antiplatelet in association&#xD;
&#xD;
        -  No antithrombotic treatement&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 7, 2018</start_date>
  <completion_date type="Actual">October 10, 2018</completion_date>
  <primary_completion_date type="Actual">October 10, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Any-severity fall-related hemorrhagic events rate</measure>
    <time_frame>The inclusion day</time_frame>
    <description>All reported hemorrhagic events after a fall</description>
  </primary_outcome>
  <enrollment type="Actual">157</enrollment>
  <condition>In-hospital Falls</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized patients in internal medicine unit for whom an in-hospital fall was reported&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hospitalized patients in internal medicine unit in Rennes University Hospital, from&#xD;
             1/01/2017 to 31/12/2017&#xD;
&#xD;
          -  Age over 18&#xD;
&#xD;
          -  In-hospital fall reported in unwanted event database&#xD;
&#xD;
          -  Separated inclusion for each fall in the same patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Adults on legal protection (safeguarding justice, trusteeship, guardianship) or&#xD;
             deprived of liberty&#xD;
&#xD;
          -  Patient opposed to inculsion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Patrick Jego, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 26, 2018</study_first_submitted>
  <study_first_submitted_qc>September 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2018</study_first_posted>
  <last_update_submitted>December 17, 2018</last_update_submitted>
  <last_update_submitted_qc>December 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>In-hospital falls</keyword>
  <keyword>fall-related bleeding</keyword>
  <keyword>anticoagulant-related bleeding</keyword>
  <keyword>antiplatelet-related bleeding</keyword>
  <keyword>antithrombotic-related bleeding</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

